Section Arrow
RLMD.NASDAQ
- Relmada Therapeutics
Quotes are at least 15-min delayed:2025/11/05 04:40 EST
Pre Market
Last
 2.4
-0.37 (-13.36%)
Bid
2.36
Ask
2.48
High 2.57 
Low 2.4 
Volume 13361 
Regular Hours
Last
 2.77
+0.57 (+25.91%)
Day High 
2.81 
Prev. Close
2.2 
1-M High
2.63 
Volume 
22.69M 
Bid
2.36
Ask
2.48
Day Low
2.19 
Open
2.21 
1-M Low
1.8033 
Market Cap 
73.02M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.27 
20-SMA 2.17 
50-SMA 1.81 
52-W High 3.425 
52-W Low 0.2404 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.20/-2.76
Enterprise Value
73.02M
Balance Sheet
Book Value Per Share
0.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5-0.44-8.09%-- 
Pre Market 5.23 +0.23 +4.60%
RANIRani Therapeutics Holdings2.38+0.23+10.70%-- 
Pre Market 2.41 +0.03 +1.26%
PRLDPrelude Therapeutics1.76-2.22-55.78%-- 
Pre Market 1.63 -0.13 -7.39%
SRPTSarepta Therapeutics16.2-8.25-33.74%15.76PE
Pre Market 16.81 +0.61 +3.77%
RLMDRelmada Therapeutics2.77+0.57+25.91%-- 
Pre Market 2.4 -0.37 -13.36%
Quotes are at least 15-min delayed:2025/11/05 04:40 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.